Haemonetics
195 hedge funds and large institutions have $2.32B invested in Haemonetics in 2013 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 72 increasing their positions, 76 reducing their positions, and 25 closing their positions.
16% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 25
8% more capital invested
Capital invested by funds: $2.16B → $2.32B (+$166M)
1.83% more ownership
Funds ownership: 105.19% → 107.02% (+1.8%)
2% more funds holding
Funds holding: 192 → 195 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 76
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
+$39.4M |
| 2 |
VBA
Van Berkom & Associates
Montreal,
Quebec, Canada
|
+$37.4M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$27.6M |
| 4 |
HIM
Hermes Investment Management
London Uk,
United Kingdom
|
+$27.4M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$21.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$52.5M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$18.2M |
| 3 |
Neuberger Berman Group
New York
|
-$12M |
| 4 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$11.4M |
| 5 |
RA
Royce & Associates
New York
|
-$8.94M |
HAE Hedge Fund Activity: Q4 2013 in Review
195 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2013, worth a combined $2.32B — up 7.7% from $2.16B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new HAE positions and 25 closed out — a net gain of 4 holders — while 72 added to existing stakes and 76 trimmed.
The largest buyer was Barrow, Hanley, Mewhinney & Strauss, opening a new position worth an estimated $39.4M. The largest seller was William Blair & Company, cutting an estimated $52.5M.
- 195 institutional investors held Haemonetics (HAE) as of Q4 2013, up from 192 in Q3 2013.
- Funds reported $2.32B of Haemonetics stock for Q4 2013, up 7.7% quarter-over-quarter.
- 29 funds opened new Haemonetics positions in Q4 2013 and 25 closed out, a net change of +4 holders.
- The largest Haemonetics buyer in Q4 2013 was Barrow, Hanley, Mewhinney & Strauss, an estimated $39.4M added.
- The largest Haemonetics seller in Q4 2013 was William Blair & Company, an estimated $52.5M sold.
Based on aggregated 13F filings for Q4 2013.